Profile data is unavailable for this security.
About the company
Kopran Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (API). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include amoxycillin, ampicillin, cloxacillin, amoxy clauv, flucloxacillin, and phenoxy methyl penicillin. Its non-penicillin-based finished oral dosage forms include macrolides, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, gastroenterology, and respiratory. It has a portfolio, producing over 100 dosage forms. These include tablets, capsules, dry powder, suspension and injectables. Its subsidiary, Kopran Research Laboratories Ltd, manufactures a range of APIs, including Atenolol and Sterile Carbapenems.
- Revenue in INR (TTM)6.20bn
- Net income in INR165.43m
- Incorporated1958
- Employees1.02k
- LocationKopran LtdParijat House1076, Dr. E. Moses Road, Worli9917MUMBAI 400018IndiaIND
- Phone+91 2 243661111
- Fax+91 2 224950363
- Websitehttps://www.kopran.com/
More ▼
Mergers & acquisitions
| Acquired company | KOPRAN:NSI since announced | Transaction value |
|---|---|---|
| Kopran Laboratories Ltd | -21.75% | 23.82m |
Data delayed at least 15 minutes, as of Feb 16 2026 06:59 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Albert David Ltd | 3.23bn | 96.12m | 4.28bn | 1.81k | 44.55 | -- | 23.18 | 1.33 | 16.84 | 16.84 | 565.37 | -- | -- | -- | -- | 1,787,412.00 | -- | 8.95 | -- | 11.63 | 64.95 | 59.69 | 2.98 | 11.56 | -- | -4.67 | -- | 13.64 | -4.61 | 1.51 | -77.19 | -2.14 | -0.7463 | -6.51 |
| Medicamen Biotech Ltd | 1.65bn | 101.58m | 4.79bn | 376.00 | 45.04 | 1.63 | 32.27 | 2.90 | 7.84 | 7.84 | 121.55 | 216.61 | 0.5033 | 1.27 | 2.46 | 4,387,495.00 | 2.59 | 4.69 | 3.39 | 6.63 | 50.32 | 38.01 | 5.15 | 8.13 | 1.81 | 2.40 | 0.1231 | 10.57 | -9.35 | 5.31 | -34.97 | -11.77 | -35.60 | 14.87 |
| Kilitch Drugs (India) Ltd | 2.09bn | 279.59m | 5.72bn | 187.00 | 19.24 | 2.15 | 19.68 | 2.73 | 17.00 | 17.00 | 127.35 | 151.97 | 0.6366 | 14.84 | 2.55 | 11,200,870.00 | 8.06 | 5.16 | 10.47 | 7.38 | 35.71 | 35.37 | 12.66 | 8.41 | 2.37 | 4.80 | 0.2404 | 0.00 | 28.47 | 30.05 | 82.86 | 99.64 | 34.88 | -- |
| Shri Ahimsa Naturals Ltd | 1.16bn | 266.73m | 6.17bn | -- | 17.99 | 3.64 | 21.65 | 5.34 | 14.65 | 14.65 | 61.23 | 72.37 | 0.7957 | 1.80 | 4.75 | -- | 18.36 | 25.55 | 19.42 | 31.51 | 48.63 | 53.50 | 23.07 | 25.19 | 12.68 | -- | 0.00 | -- | 22.86 | 34.75 | 17.31 | 78.70 | 53.34 | -- |
| Anlon Healthcare Ltd | 1.70bn | 346.64m | 6.46bn | 101.00 | 16.49 | -- | 17.59 | 3.80 | 7.37 | 7.37 | 37.66 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 38.31 | -- | 20.39 | -- | -- | 11.05 | -- | -- | 80.65 | -- | 112.46 | -- | -- | -- |
| Kopran Ltd | 6.20bn | 165.43m | 6.48bn | 1.02k | 39.31 | -- | 19.41 | 1.05 | 3.41 | 3.41 | 128.28 | -- | -- | -- | -- | 6,052,426.00 | -- | 7.85 | -- | 11.25 | 34.20 | 32.04 | 2.67 | 8.66 | -- | 2.39 | -- | 29.60 | 2.44 | 11.86 | -24.34 | 12.90 | 33.20 | -- |
| Fabtech Technologies Ltd | -100.00bn | -100.00bn | 7.22bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.46 | -- | 70.67 | -- | -- | -- |
| Accent Microcell Ltd | 2.78bn | 346.64m | 7.72bn | 192.00 | 21.12 | 3.09 | 19.84 | 2.78 | 15.24 | 15.24 | 122.20 | 104.07 | 1.12 | 4.14 | 5.32 | 14,474,330.00 | 13.99 | -- | 15.95 | -- | 39.96 | -- | 12.47 | -- | 3.01 | 76.48 | 0.0046 | -- | 7.77 | -- | 9.60 | -- | -- | -- |
| Remus Pharmaceuticals Ltd | 7.48bn | 325.59m | 7.98bn | 68.00 | 21.78 | 2.60 | 18.15 | 1.07 | 31.11 | 31.11 | 701.20 | 260.51 | 1.89 | 9.07 | 7.21 | 109,981,700.00 | 10.44 | 14.37 | 18.44 | 28.60 | 13.01 | 19.39 | 5.51 | 8.39 | 1.07 | 35.59 | 0.0452 | 3.59 | 191.93 | 120.44 | 34.98 | 104.56 | 48.07 | -- |
| Anuh Pharma Ltd | 7.68bn | 418.22m | 8.14bn | 295.00 | 19.44 | -- | 15.36 | 1.06 | 4.17 | 4.17 | 76.65 | -- | -- | -- | -- | 26,023,040.00 | -- | 10.41 | -- | 17.00 | 22.25 | 23.95 | 5.45 | 7.35 | -- | 116.27 | -- | 26.59 | 2.24 | 16.60 | -21.16 | 27.05 | -10.78 | 16.89 |
| Themis Medicare Ltd | 3.41bn | -269.80m | 8.37bn | 1.76k | -- | 2.20 | -- | 2.45 | -2.92 | -2.92 | 37.53 | 41.29 | 0.5758 | 1.78 | 1.82 | 1,937,953.00 | -4.55 | 10.17 | -6.33 | 14.38 | 63.17 | 60.61 | -7.91 | 13.52 | 1.28 | -1.55 | 0.201 | 9.36 | 6.22 | 15.00 | -31.46 | 3.78 | 21.58 | 23.36 |
| Sigachi Industries Ltd | 5.06bn | -550.46m | 8.79bn | 1.10k | -- | 1.73 | -- | 1.74 | -1.46 | -1.46 | 13.20 | 13.29 | 0.6316 | 2.40 | 2.80 | 4,624,222.00 | -6.70 | 12.29 | -9.77 | 16.21 | 52.83 | 51.93 | -10.62 | 14.80 | 1.27 | 5.53 | 0.2436 | 4.23 | 22.38 | 28.55 | 21.66 | 27.91 | 48.87 | -- |
Data as of Feb 16 2026. Currency figures normalised to Kopran Ltd's reporting currency: Indian Rupee INR
0.28%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Dimensional Fund Advisors LPas of 05 Feb 2026 | 60.31k | 0.13% |
| American Century Investment Management, Inc.as of 05 Feb 2026 | 46.65k | 0.10% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 20.99k | 0.04% |
| DFA Australia Ltd.as of 31 Dec 2025 | 5.74k | 0.01% |
| Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025 | 788.00 | 0.00% |
| Bandhan AMC Ltd.as of 31 Jan 2026 | 333.00 | 0.00% |
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
